DOI:
10.1055/s-00025476
Endoscopy International Open
LinksClose Window
References
Hayashi H, Kohno T, Ueno H. et al.
Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer.
Pancreas 2017;
46: 335-340
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.